Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KMDA Stock Forecast 2026-2027
$8.17
Current Price
$471.91M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KMDA Price Targets
+83.6%
To High Target of $15.00
+59.1%
To Median Target of $13.00
+34.6%
To Low Target of $11.00
KMDA Price Momentum
+1.4%
1 Week Change
+12.2%
1 Month Change
+14.1%
1 Year Change
+15.7%
Year-to-Date Change
-10.7%
From 52W High of $9.15
+47.5%
From 52W Low of $5.54
📊 TOP ANALYST CALLS
Did KMDA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kamada is one of their latest high-conviction picks.
Latest KMDA Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, KMDA has a bullish consensus with a median price target of $13.00 (ranging from $11.00 to $15.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $8.17, the median forecast implies a 59.1% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Wasserman at Benchmark, projecting a 83.6% upside. Conversely, the most conservative target is provided by Andrew Fein at HC Wainwright & Co., suggesting a 34.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KMDA Analyst Ratings
3
Buy
0
Hold
0
Sell
KMDA Price Target Range
Low
$11.00
Average
$13.00
High
$15.00
Current: $8.17
Latest KMDA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KMDA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $13.00 |
| May 15, 2025 | Benchmark | Robert Wasserman | Buy | Reiterates | $15.00 |
| Mar 21, 2025 | Benchmark | Robert Wasserman | Buy | Initiates | $15.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Jul 3, 2024 | Stifel | Annabel Samimy | Buy | Initiates | $18.00 |
| May 9, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| May 25, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Mar 16, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Feb 2, 2018 | Chardan Capital | Buy | Initiates | $7.00 | |
| Nov 13, 2015 | Jefferies | Buy | Maintains | $8.00 | |
| Jun 25, 2013 | Morgan Stanley | Equal-Weight | Initiates | $N/A | |
| Jun 25, 2013 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jun 25, 2013 | Jefferies | Buy | Initiates | $N/A |
Kamada Ltd. (KMDA) Competitors
The following stocks are similar to Kamada based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kamada Ltd. (KMDA) Financial Data
Kamada Ltd. has a market capitalization of $471.91M with a P/E ratio of 23.3x. The company generates $174.79M in trailing twelve-month revenue with a 11.7% profit margin.
Revenue growth is +12.6% quarter-over-quarter, while maintaining an operating margin of +16.6% and return on equity of +7.9%.
Valuation Metrics
Market Cap
$471.91M
Enterprise Value
$420.23M
P/E Ratio
23.3x
PEG Ratio
0.8x
Price/Sales
2.7x
Growth & Margins
Revenue Growth (YoY)
+12.6%
Gross Margin
+42.0%
Operating Margin
+16.6%
Net Margin
+11.7%
EPS Growth
+37.1%
Financial Health
Cash/Price Ratio
+15.0%
Current Ratio
4.0x
Debt/Equity
4.3x
ROE
+7.9%
ROA
+4.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kamada Ltd. (KMDA) Business Model
About Kamada Ltd.
What They Do
Develops plasma-derived protein therapeutics.
Business Model
Kamada Ltd. generates revenue by developing, producing, and marketing specialty biopharmaceutical products that target unmet clinical needs. The company focuses on therapies for rare diseases, particularly in immunology and critical care, and collaborates with global healthcare companies to enhance distribution and market access.
Additional Information
With a strong emphasis on research and development, Kamada is committed to expanding its product pipeline and therapeutic applications. This biopharmaceutical company is headquartered in Israel and aims to improve patient care and quality of life through innovative medical solutions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
420
CEO
Country
Israel
IPO Year
2010
Website
www.kamada.comKamada Ltd. (KMDA) Latest News & Analysis
Latest News
Quick Summary
Kamada Ltd. has received a two-year extension from Canadian Blood Services to supply four plasma-derived products, valued at $10-$14 million, ensuring ongoing sales from Q2-26 to Q1-28.
Why It Matters
Kamada Ltd.'s contract extension with Canadian Blood Services ensures steady revenue of $10-$14 million, boosting financial stability and investor confidence in the company's growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kamada Ltd. (NASDAQ: KMDA) announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD).
Why It Matters
Kamada Ltd.'s discontinuation of the Phase 3 trial may signal setbacks in drug development, impacting stock value and investor confidence in future prospects.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Kamada Ltd. (KMDA) has announced the discontinuation of its Phase 3 inhaled AAT clinical trial and provided updates on its financial outlook.
Why It Matters
Kamada Ltd.'s discontinuation of its Phase 3 inhaled AAT trial may signal setbacks in drug development, impacting future revenue potential and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
2 months ago
Quick Summary
Kamada Ltd. (KMDA) will hold its Q3 2025 earnings call on November 10, 2025, at 8:30 AM EST, featuring CEO Amir London and CFO Chaime Orlev.
Why It Matters
Kamada Ltd.'s Q3 2025 earnings call provides key insights into the company's financial performance and future outlook, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Kamada Ltd. (NASDAQ: KMDA) announced its financial results for Q3 and the first nine months of 2025, focusing on its biopharmaceutical products for rare conditions.
Why It Matters
Kamada Ltd.'s financial results can indicate growth or decline in revenue, impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Kamada (KMDA) Misses Q3 Earnings Estimates
2 months ago
Quick Summary
Kamada (KMDA) reported Q3 earnings of $0.09 per share, below the Zacks Consensus Estimate of $0.10, but up from $0.07 per share a year earlier.
Why It Matters
Kamada's earnings miss signals potential weakness in performance, which may lead to negative sentiment and impact its stock price and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About KMDA Stock
What is Kamada Ltd.'s (KMDA) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Kamada Ltd. (KMDA) has a median price target of $13.00. The highest price target is $15.00 and the lowest is $11.00.
Is KMDA stock a good investment in 2026?
According to current analyst ratings, KMDA has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KMDA stock?
Wall Street analysts predict KMDA stock could reach $13.00 in the next 12 months. This represents a 59.1% increase from the current price of $8.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kamada Ltd.'s business model?
Kamada Ltd. generates revenue by developing, producing, and marketing specialty biopharmaceutical products that target unmet clinical needs. The company focuses on therapies for rare diseases, particularly in immunology and critical care, and collaborates with global healthcare companies to enhance distribution and market access.
What is the highest forecasted price for KMDA Kamada Ltd.?
The highest price target for KMDA is $15.00 from Robert Wasserman at Benchmark, which represents a 83.6% increase from the current price of $8.17.
What is the lowest forecasted price for KMDA Kamada Ltd.?
The lowest price target for KMDA is $11.00 from Andrew Fein at HC Wainwright & Co., which represents a 34.6% increase from the current price of $8.17.
What is the overall KMDA consensus from analysts for Kamada Ltd.?
The overall analyst consensus for KMDA is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are KMDA stock price projections?
Stock price projections, including those for Kamada Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 3:26 AM UTC